FDA says cancer still a priority as it approves AZ’s Koselugo, a first for nerve tumors

With the approval of the first therapy for a rare pediatric cancer Friday, FDA is assuring cancer patients that getting treatments into their hands is still a priority for the agency during the COVID-19 pandemic.

FDA approved Koselugo selumetinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat pediatric patients two years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. The genetic disorder causes tumors to grow on nerves...